ABT

Abbott Laboratories
Pharmaceuticals

Cash & Equivalents

$8.52B
As of 2025-12-31
Current Price: $100.30 (as of 2026-04-12)

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $8.52B
Total Obligations: -$30.63B
$-22.11B
Per share: $-12.70
Period: 2025-12-31

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $8.52B
AR: $7.93B
Total Obligations: -$30.63B
$-14.18B
Per share: $-8.15
Period: 2025-12-31

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $8.52B
AR: $7.93B
Inventory: $6.49B
Total Obligations: -$30.63B
$-7.69B
Per share: $-4.42
Period: 2025-12-31

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-22.11B$-12.70
Liquid Liquidation Value$-14.18B$-8.15
Operating Liquidation Value$-7.69B$-4.42

Key Components (as of 2025-12-31)

Cash & Equivalents$8.52B
Accounts Receivable$7.93B
Inventory$6.49B
Current Liabilities$16.50B
Long-term Debt$12.93B
Op. Lease Liability$1.21B
Finance LeaseN/A
Shares Outstanding1.74B

Explore all 214 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2025-12-31 $8.52B $7.93B $6.49B N/A $16.50B $12.93B $1.21B N/A
2025-09-30 $7.51B $8.14B $6.71B N/A $14.58B $11.60B N/A N/A
2025-06-30 $6.95B $7.97B $6.95B N/A $13.44B $12.93B N/A N/A
2025-03-31 $6.53B $7.33B $6.64B N/A $13.00B $12.74B N/A N/A
2024-12-31 $7.62B $6.92B $6.19B N/A $14.16B $14.12B $1.15B N/A
2024-09-30 $7.56B $7.05B $6.81B N/A $14.90B $12.82B N/A N/A
2024-06-30 $6.99B $6.85B $6.81B N/A $13.76B $13.14B N/A N/A
2024-03-31 $6.28B $6.61B $6.83B N/A $14.02B $12.58B N/A N/A

SEC Filings

PeriodFormFiledLink
2025-12-31 10-K 2026-02-20 View
2025-09-30 10-Q 2025-10-29 View
2025-06-30 10-Q 2025-07-30 View
2025-03-31 10-Q 2025-04-30 View
2024-12-31 10-K 2025-02-21 View
2024-09-30 10-Q 2024-10-31 View
2024-06-30 10-Q 2024-07-31 View
2024-03-31 10-Q 2024-05-02 View